High Tide Scheduled to Announce Q2 Earnings on June 15
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 14 2026
0mins
Source: seekingalpha
- Earnings Announcement Date: High Tide (HITI) is set to release its Q2 earnings on June 15 after market close, with a consensus EPS estimate of -$0.02, reflecting a 50% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The anticipated revenue for Q2 is $125.53 million, representing an 8.9% year-over-year decline, which highlights the volatility in the cannabis sector that may exert pressure on the company's performance and investor confidence.
- Historical Performance Review: Over the past two years, High Tide has only beaten EPS estimates 25% of the time, yet has surpassed revenue estimates 100% of the time, demonstrating stability in revenue growth despite the need for improvement in profitability metrics.
- Industry Context: While High Tide shows strong revenue growth, the overall volatility in the cannabis industry remains a significant risk factor that could impact future performance and investor decision-making.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HITI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HITI
Wall Street analysts forecast HITI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.270
Low
7.50
Averages
7.50
High
7.50
Current: 2.270
Low
7.50
Averages
7.50
High
7.50
About HITI
High Tide Inc. is a retail-focused cannabis company. The Company’s segments include bricks-and-mortar, e-commerce and medical cannabis distribution. Its Bricks-and-mortar segment includes the Company’s Canadian bricks-and-mortar locations. Its E-commerce segment includes the Company’s United States and international subsidiaries and supports the distribution of accessories and other items to the United States. The medical cannabis distribution segment includes the medical cannabis distribution operations. It offers a suite of proprietary brands which include Dopezilla, Atomik, Puff Puff Pass, Vodka Glass, Queen of Bud, and Cabana Cannabis Co. Canna Cabana is the Company’s primary retail cannabis business, offering the retail sale of various cannabis products and accessories through its provincially authorized cannabis retail store locations. Canna Cabana operates a retail cannabis chain with approximately 219 branded stores operating across Canada.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
High Tide Enhances Compliance with Shareholder Rights Plans
- Shareholder Rights Plan Update: High Tide's board has approved a Temporary Shareholder Rights Plan and an Amended and Restated Shareholder Rights Plan to ensure compliance with cannabis laws and maintain licenses, thereby enhancing shareholder fairness in acquisition offers.
- Compliance Safeguards: The Amended Plan expands the definition of 'Acquiring Person' to include retail operators in Ontario and British Columbia, ensuring the company does not violate regulations, thus reducing legal risks and protecting corporate interests.
- Interim Measures Implementation: The board adopted the Temporary Shareholder Rights Plan as a stopgap due to the need for shareholder approval to amend the existing plan, allowing the company to address new retail operator restrictions while awaiting ratification.
- Future Outlook: If ratified, the Amended Shareholder Rights Plan will be effective for three years, further solidifying the company's market position and enhancing its competitiveness in a rapidly evolving industry landscape.
See More
High Tide Adopts Shareholder Rights Plans to Ensure Compliance
- Shareholder Rights Plans: High Tide Inc. has adopted a Temporary Shareholder Rights Plan and an Amended and Restated Shareholder Rights Plan approved by its board, aimed at ensuring compliance with cannabis laws and maintaining its licenses, thereby protecting shareholder interests and enhancing the company's response to acquisition offers.
- Compliance Expansion: The Amended Plan expands the definition of 'Acquiring Person' to include retail operators in Ontario and British Columbia, ensuring the company does not violate relevant regulations, which will help maintain its market position and legal operations.
- Interim Measures: The board adopted the Temporary Shareholder Rights Plan as a transitional measure pending shareholder approval of the Amended Plan, ensuring compliance under new retail operator restrictions and maintaining operational integrity.
- Future Outlook: If ratified by shareholders, the Amended Shareholder Rights Plan will be effective for three years, providing the company with a comprehensive rights plan that enhances its competitiveness and stability in the market.
See More
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect directly with pharmacies and healthcare professionals in Germany, addressing patient demand for high-quality products.
- Positive Industry Response: The event garnered positive feedback from patients and healthcare professionals, indicating a rising demand for high-quality, trusted cannabis products, which enhances Remexian's competitive edge in the market.
- Strategic Investment: By continuously broadening its product offerings and strengthening supply chain relationships, Remexian aims to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing High Tide's strategy of leveraging its Canadian strengths for global diversification.
See More
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect Canadian brands directly with pharmacies and healthcare professionals in Germany.
- Industry Opportunities: Germany is viewed as a significant growth opportunity in the global medical cannabis industry, and Remexian's participation not only enhances its reputation as a trusted importer of premium products but also fosters relationships with healthcare professionals, facilitating the expansion of its pharmacy network.
- Competitive Advantage: High Tide's CEO Raj Grover stated that by continuously broadening its product offerings and strengthening supply chain relationships, Remexian is positioning itself to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing its unique procurement capabilities and market strategy.
See More
High Tide Inc Reports Record Q2 Earnings with 30% Revenue Growth
- Significant Revenue Growth: High Tide Inc reported a record revenue of $179.3 million in Q2, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and indicating strong market performance and expansion potential.
- Record Gross Margin: The company achieved a gross profit of $48.4 million with a gross margin of 27%, the highest in eight quarters, showcasing improved profitability in its medical cannabis distribution segment, particularly in the German market.
- Strong Membership Growth: Cabana Club membership reached 2.65 million, up 39% year-over-year, with elite memberships soaring by 84%, which not only enhances customer loyalty but also lays a solid foundation for future sales growth.
- Enhanced Financial Flexibility: High Tide secured a $40 million credit facility with Bank of Montreal, boosting its financial flexibility; despite free cash flow being $1.5 million, the company is actively investing to support future expansion plans.
See More
High Tide Reports Q2 Earnings Beat, Shares Surge 21%
- Record Revenue: High Tide reported a record revenue of C$179.3 million for Q2 FY2026, reflecting a 30% year-over-year increase and surpassing estimates of C$171.15 million, indicating strong performance in the retail sector.
- Stable Market Share: Canna Cabana maintained a 12% market share, and excluding British Columbia's restrictions, its share increased to 14%, up from 13% last year, demonstrating robust growth in a competitive market.
- Improved Profitability: Adjusted EBITDA reached a record C$13.9 million, a 73% year-over-year increase and the fastest growth in nine quarters, despite having three fewer days in the quarter, showcasing effective cost control and operational efficiency.
- Medical Cannabis Distribution Growth: Remexian achieved a record distribution of 7.6 tonnes of medical cannabis in Germany, marking a 49% year-over-year and 21% sequential increase, further solidifying High Tide's position in the international market.
See More
High Tide Enhances Compliance with Shareholder Rights Plans
- Shareholder Rights Plan Update: High Tide's board has approved a Temporary Shareholder Rights Plan and an Amended and Restated Shareholder Rights Plan to ensure compliance with cannabis laws and maintain licenses, thereby enhancing shareholder fairness in acquisition offers.
- Compliance Safeguards: The Amended Plan expands the definition of 'Acquiring Person' to include retail operators in Ontario and British Columbia, ensuring the company does not violate regulations, thus reducing legal risks and protecting corporate interests.
- Interim Measures Implementation: The board adopted the Temporary Shareholder Rights Plan as a stopgap due to the need for shareholder approval to amend the existing plan, allowing the company to address new retail operator restrictions while awaiting ratification.
- Future Outlook: If ratified, the Amended Shareholder Rights Plan will be effective for three years, further solidifying the company's market position and enhancing its competitiveness in a rapidly evolving industry landscape.
See More
High Tide Adopts Shareholder Rights Plans to Ensure Compliance
- Shareholder Rights Plans: High Tide Inc. has adopted a Temporary Shareholder Rights Plan and an Amended and Restated Shareholder Rights Plan approved by its board, aimed at ensuring compliance with cannabis laws and maintaining its licenses, thereby protecting shareholder interests and enhancing the company's response to acquisition offers.
- Compliance Expansion: The Amended Plan expands the definition of 'Acquiring Person' to include retail operators in Ontario and British Columbia, ensuring the company does not violate relevant regulations, which will help maintain its market position and legal operations.
- Interim Measures: The board adopted the Temporary Shareholder Rights Plan as a transitional measure pending shareholder approval of the Amended Plan, ensuring compliance under new retail operator restrictions and maintaining operational integrity.
- Future Outlook: If ratified by shareholders, the Amended Shareholder Rights Plan will be effective for three years, providing the company with a comprehensive rights plan that enhances its competitiveness and stability in the market.
See More
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect directly with pharmacies and healthcare professionals in Germany, addressing patient demand for high-quality products.
- Positive Industry Response: The event garnered positive feedback from patients and healthcare professionals, indicating a rising demand for high-quality, trusted cannabis products, which enhances Remexian's competitive edge in the market.
- Strategic Investment: By continuously broadening its product offerings and strengthening supply chain relationships, Remexian aims to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing High Tide's strategy of leveraging its Canadian strengths for global diversification.
See More
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect Canadian brands directly with pharmacies and healthcare professionals in Germany.
- Industry Opportunities: Germany is viewed as a significant growth opportunity in the global medical cannabis industry, and Remexian's participation not only enhances its reputation as a trusted importer of premium products but also fosters relationships with healthcare professionals, facilitating the expansion of its pharmacy network.
- Competitive Advantage: High Tide's CEO Raj Grover stated that by continuously broadening its product offerings and strengthening supply chain relationships, Remexian is positioning itself to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing its unique procurement capabilities and market strategy.
See More
High Tide Inc Reports Record Q2 Earnings with 30% Revenue Growth
- Significant Revenue Growth: High Tide Inc reported a record revenue of $179.3 million in Q2, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and indicating strong market performance and expansion potential.
- Record Gross Margin: The company achieved a gross profit of $48.4 million with a gross margin of 27%, the highest in eight quarters, showcasing improved profitability in its medical cannabis distribution segment, particularly in the German market.
- Strong Membership Growth: Cabana Club membership reached 2.65 million, up 39% year-over-year, with elite memberships soaring by 84%, which not only enhances customer loyalty but also lays a solid foundation for future sales growth.
- Enhanced Financial Flexibility: High Tide secured a $40 million credit facility with Bank of Montreal, boosting its financial flexibility; despite free cash flow being $1.5 million, the company is actively investing to support future expansion plans.
See More
High Tide Reports Q2 Earnings Beat, Shares Surge 21%
- Record Revenue: High Tide reported a record revenue of C$179.3 million for Q2 FY2026, reflecting a 30% year-over-year increase and surpassing estimates of C$171.15 million, indicating strong performance in the retail sector.
- Stable Market Share: Canna Cabana maintained a 12% market share, and excluding British Columbia's restrictions, its share increased to 14%, up from 13% last year, demonstrating robust growth in a competitive market.
- Improved Profitability: Adjusted EBITDA reached a record C$13.9 million, a 73% year-over-year increase and the fastest growth in nine quarters, despite having three fewer days in the quarter, showcasing effective cost control and operational efficiency.
- Medical Cannabis Distribution Growth: Remexian achieved a record distribution of 7.6 tonnes of medical cannabis in Germany, marking a 49% year-over-year and 21% sequential increase, further solidifying High Tide's position in the international market.
See More
